Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

作者
Othman Al‐Sawaf,Kirsten Fischer,Anja Engelke,Natali Pflug,Michael Hallek,Valentin Goede
出处
期刊:Drug Design Development and Therapy [Dove Medical Press]
卷期号:Volume11: 295-304 被引量:23
标识
DOI:10.2147/dddt.s104869
摘要

For decades, treatment of chronic lymphocytic leukemia (CLL) has been based on chemotherapy. This changed when the first CD20 antibody rituximab was introduced. Since 2008, the combination of chemotherapy and CD20 antibodies has become the standard of care for most patients, and a significant fraction of patients had very long-lasting remissions after chemoimmunotherapy. Despite the improvement of response rates and overall survival (OS) by the use of chemoimmunotherapy, most CLL patients will relapse eventually. One approach to achieve more durable responses was the development of obinutuzumab (GA101), a new type of CD20 antibody that has unique molecular and functional characteristics. Obinutuzumab is a type II fully humanized CD20 antibody that binds to a partly different epitope of the CD20 protein than rituximab and due to its glycoengineered design induces greater antibody-dependent cell-mediated cytotoxicity (ADCC). Initial preclinical observations of a more effective B-cell depletion have been successfully reproduced in clinical trials with CLL patients. This review summarizes results of preclinical as well as clinical studies with obinutuzumab and provides an outlook on its future role in the therapy of CLL.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
上官若男的应助被Jayh4n采纳,获得10
2秒前
SchoLar完成签到 ,获得积分10
2秒前
香蕉觅云的应助被起司采纳,获得60
3秒前
琳敏完成签到,获得积分10
4秒前
何永灿发布了新的文献求助10
4秒前
4秒前
康子浩发布了新的文献求助10
4秒前
4秒前
elynn发布了新的文献求助10
4秒前
成就老虎发布了新的文献求助10
5秒前
温赢发布了新的文献求助10
5秒前
5秒前
5秒前
6秒前
6秒前
7秒前
害羞的飞槐完成签到,获得积分10
7秒前
haoliu完成签到,获得积分10
7秒前
7秒前
8秒前
司徒元瑶完成签到 ,获得积分10
8秒前
8秒前
传奇3的应助被yeah采纳,获得10
9秒前
气11完成签到,获得积分10
9秒前
9秒前
爱吃果冻发布了新的文献求助10
10秒前
白衣修身发布了新的文献求助10
11秒前
11秒前
王壬发布了新的文献求助10
11秒前
11秒前
11秒前
12秒前
rxir发布了新的文献求助20
13秒前
13秒前
LZX完成签到,获得积分10
13秒前
道友且慢完成签到,获得积分10
14秒前
14秒前
15秒前
Jayh4n发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163643
求助须知:如何正确求助?哪些是违规求助? 9557771
关于积分的说明 21741795
捐赠科研通 7754289
什么是DOI,文献DOI怎么找? 3428316
关于科研通互助平台的介绍 2552989
邀请新用户注册赠送积分活动 2472943